Q-Line Biotech Limited (QLINE)
சுருக்கம்
The board meets on 12 Nov 2026 to consider the Q2 FY27 results.
பங்குச் சந்தை செயல்பாடு12 நவ. 2026
- டெலிவரி
- 80.9% எதிர் சராசரி 66.82%
- வால்யூம் அதன் சராசரியுடன் ஒப்பீடு
- 0.8×
நிகழ்வுகள்
- அடுத்த முடிவுகள்
- 12 நவ. 2026 (Q2 FY27)
- இயக்குநர் குழுக் கூட்ட அறிவிப்பு
- 5 செப். 2026
பங்குச் சந்தைத் தரவு. ஒவ்வொரு எண்ணும் அதன் சொந்தப் பக்கம் காட்டும் வடிவத்திலேயே; தேதிகள் தரவின் தேதிகள். தகவலுக்கு மட்டுமே, முதலீட்டு ஆலோசனை அல்ல.
📈 பங்கு விலை & நிகழ்வுகள்
Q2 FY27 முடிவுகள்
📅 அடுத்த நிதி முடிவுகள்: 12 நவ. 2026 (இயக்குநர் குழுக் கூட்டம்)Q-Line Biotech Limited-இன் இயக்குநர் குழுக் கூட்டம் 12 நவ. 2026 அன்று நடைபெறுகிறது; அதில் அதன் Q2 FY27 முடிவுகள் பரிசீலிக்கப்படும் (ஜூலை-செப்டம்பர் 2026).
QLINE டெலிவரி சதவீதம்
க்கான NSE EOD தரவு
On Thu, 12 Nov 2026, 80.9% of the QLINE shares traded on NSE were taken to delivery, against the stock's own 20-session average of 66.82%. Delivery was unusually high while the price barely moved (+0.97%).
கடந்த 5 அமர்வுகளில் டெலிவரி: 81.9% · 72.8% · 73.7% · 79.1% · 80.9%
பங்குச் சந்தை வெளியிட்டவற்றின் விளக்கம், பரிந்துரை அல்ல. "accumulation" அல்லது "லாங் பில்டப்" போன்ற பெயர்கள் எண்களில் உள்ள ஒரு வடிவத்தை குறிக்கின்றன. டெலிவரி எவ்வாறு பகுப்பாய்வு செய்யப்படுகிறது
📢 சமீபத்திய கார்ப்பரேட் அறிவிப்புகள்
Q-Line Biotech Limited submitted a clarification regarding a clerical error in the subject line of a previous filing, confirming the correct time of its upcoming Board Meeting is 4:15 P.M. instead of 3:00 P.M. The meeting is scheduled to be held on Thursday, November 12, 2026. The primary agenda includes considering and approving the unaudited standalone and consolidated financial results for the half year ended September 30, 2026.
- Clarified board meeting time to 04:15 p.m. due to a prior clerical error indicating 3:00 P.M.
- Board meeting date scheduled for Thursday, 12th Day of November 2026
- Meeting agenda covers half-year financial results ended September 30, 2026
Q-Line Biotech Limited has submitted its compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended September 30, 2026. The certificate issued by Registrar and Share Transfer Agent (RTA) Purva Sharegistry (India) Private Limited confirms that security certificates received for dematerialisation during the period were processed, confirmed or rejected, and properly mutilated/cancelled. This filing is a standard quarterly regulatory compliance disclosure with no operational or financial impact.
- Compliance certificate submitted under Regulation 74(5) of SEBI Regulations, 2018
- Covers the quarter and month ended September 30, 2026
- Issued by RTA Purva Sharegistry (India) Private Limited on October 01, 2026
- Filing submitted to the National Stock Exchange on October 08, 2026
Q-Line Biotech Limited has declared the voting results and scrutinizer's report for its 16th Annual General Meeting held on September 30, 2026. A total of 1,72,65,300 votes were polled across 2,33,28,199 total shares, representing a 74.01% turnout. All four ordinary resolutions, including the adoption of FY audited statements, re-appointment of retiring directors, and remuneration ratification for the cost auditor, were passed with requisite majority (>99.99% support).
- All 4 ordinary resolutions approved with requisite majority at the 16th AGM held on September 30, 2026
- Overall voter turnout was 74.0104%, representing 1,72,65,300 polled shares out of 2,33,28,199 total shares
- Resolution 1 (adoption of audited financial statements) passed with 100% votes in favor
- Re-appointment of directors Ajay Kumar Mahanty (100% favor) and Kuldeep Chowdhry (99.993% favor) approved
- Cost auditor remuneration for FY 2026-27 approved with 99.9954% votes in favor
Q-Line Biotech Limited has submitted the Scrutinizer's Report for its 16th Annual General Meeting held on September 30, 2026. All four ordinary resolutions placed before the shareholders were passed with an overwhelming majority (near 100% approval). The approved agenda included adopting standalone and consolidated audited financials for FY26, re-appointing directors Ajay Kumar Mahanty and Kuldeep Chowdhry, and ratifying the cost auditor's remuneration for FY27.
- All 4 ordinary resolutions approved with requisite majority at the 16th AGM held on September 30, 2026
- Adoption of FY26 standalone and consolidated financial statements passed with 100% of 17,265,300 votes in favour
- Re-appointment of director Kuldeep Chowdhry passed with 99.9930% votes in favour (1,200 votes against)
- Ratification of cost auditor remuneration for FY 2026-27 approved with 99.9954% votes in favour
Q-Line Biotech Limited has issued a dispatch notice containing web links for its FY 2025-26 Annual Report and 16th AGM Notice to shareholders whose registered emails bounced back. The 16th AGM is scheduled to be held physically on September 30, 2026, at 4:00 P.M. in Lucknow. The cut-off date to determine voting eligibility is September 23, 2026, with remote e-voting running from September 27 to September 29, 2026.
- 16th Annual General Meeting to be held on September 30, 2026, at 4:00 P.M. IST in physical mode in Lucknow
- Cut-off date for remote e-voting and voting eligibility set as September 23, 2026
- Remote e-voting period opens on September 27, 2026 (9:00 A.M.) and closes on September 29, 2026 (5:00 P.M.)
- Letter dispatched under Regulation 36(1)(b) for shareholders with undelivered/bounced email addresses
Q-Line Biotech Limited has issued a corrigendum regarding its filings dated September 07, 2026. The company clarified that due to a typographical error, the 16th Annual General Meeting was incorrectly labeled as the 37th AGM in the subject lines of two exchange intimations. There are no changes to the contents of the Annual Report for FY 2025-26 or the Notice of the AGM itself.
- Clarified typographical error referring to the 37th AGM instead of the 16th AGM
- Pertains to two previous intimations submitted on September 07, 2026
- Annual Report FY 2025-26 and AGM notice contents remain completely unchanged
Q-Line Biotech Limited has submitted its Annual Report for the financial year 2025-26 along with the Notice convening its 16th Annual General Meeting (AGM). The AGM is scheduled to be held in physical mode on September 30, 2026, at Lucknow. Key agenda items include the adoption of FY26 standalone and consolidated audited financial statements, director retirements by rotation, and ratification of cost auditor remuneration of ₹1,20,000 for FY27. In consolidated notes, the company noted that losses attributable to minority shareholders in certain subsidiaries have exceeded their equity and were absorbed by the parent company.
- 16th Annual General Meeting scheduled for September 30, 2026, at Lucknow
- Adoption of Standalone and Consolidated Audited Financial Statements for FY ended March 31, 2026
- Ratification of remuneration of ₹1,20,000 plus taxes for Cost Auditor M/s P S P & Associates for FY 2026-27
- Subsidiary minority interest presented at NIL as excess losses were absorbed by the parent company under AS 21
Q-Line Biotech Limited has issued the notice for its 16th Annual General Meeting (AGM) scheduled for September 30, 2026, at Lucknow. The cut-off date for e-voting eligibility has been fixed as September 23, 2026, with the remote voting window active between September 27 and September 29, 2026. Key agenda items include the adoption of FY2025-26 standalone and consolidated financial statements, re-appointment of retiring directors, and ratification of cost auditor remuneration of ₹1,20,000.
- 16th Annual General Meeting to be held on Wednesday, September 30, 2026, at 04:00 PM IST in physical mode at Lucknow.
- Cut-off date for determining member eligibility for remote e-voting is September 23, 2026.
- Remote e-voting commences on September 27, 2026 (9:00 AM IST) and concludes on September 29, 2026 (5:00 PM IST).
- Proposed ratification of ₹1,20,000 remuneration plus taxes for Cost Auditor M/s P S P & Associates for FY 2026-27.
Q-Line Biotech Limited held its Board of Directors meeting on September 05, 2026, approving the Board's Report and Management Discussion and Analysis Report for the financial year ended March 31, 2026. The 16th Annual General Meeting (AGM) has been scheduled for September 30, 2026, via physical mode in Lucknow. The cut-off date to determine member eligibility for e-voting is set as September 23, 2026. Additionally, the Board recommended the re-appointment of two Whole-Time Directors retiring by rotation and re-appointed M/s P S P & Associates as Cost Auditor for FY 2026-27.
- 16th Annual General Meeting scheduled for September 30, 2026, at 04:00 PM IST in Lucknow
- Cut-off date for remote e-voting and AGM voting fixed as September 23, 2026
- Remote e-voting window active from September 27, 2026 (9:00 AM) to September 29, 2026 (5:00 PM)
- Recommended re-appointment of Whole Time Directors Mr. Ajay Kumar Mahanty and Mr. Kuldeep Chowdhry
- Re-appointed M/s P S P & Associates as Cost Auditor for FY 2026-27
Q-Line Biotech Limited has executed an Amended and Restated License Agreement with Sweden-based Boule Medical AB for diagnostic reagents, consumables, and haematology analyser platforms. Under the revised terms, the license/royalty payable by Q-Line to Boule is reduced by 25%, effective retroactively from July 01, 2026. The agreement has an initial term of 5 years, extendable by another 5 years upon mutual consent. The revised arrangement also provides rationalised minimum purchase commitments, revised instrument license fees, and extended payment terms to improve cost competitiveness in institutional tenders.
- 25% reduction in license/royalty costs payable by Q-Line to Boule Medical AB
- Revised commercial and royalty terms effective retroactively from July 01, 2026
- Initial contract tenure set at 5 years, extendable for up to an additional 5 years
- Agreement incorporates rationalised minimum purchase commitments, extended payment terms, and volume-linked benefits
CARE Ratings has assigned fresh credit ratings to Q-Line Biotech Limited's bank facilities totaling Rs 221.30 crore. Long-term facilities of Rs 20.00 crore were assigned 'CARE A-; Stable', while short-term facilities of Rs 16.00 crore received 'CARE A2+'. Long-term/short-term facilities of Rs 185.30 crore (including Rs 61.55 crore in proposed limits) were assigned 'CARE A-; Stable / CARE A2+'. The ratings reflect an investment-grade profile that can assist the company in maintaining competitive borrowing costs.
- CARE Ratings assigned 'CARE A-; Stable' to Rs 20.00 crore long-term term loan facilities from Bank of Baroda
- Assigned 'CARE A-; Stable / CARE A2+' to Rs 185.30 crore long-term/short-term facilities, including Rs 123.75 crore fund-based limits
- Assigned 'CARE A2+' rating to Rs 16.00 crore short-term non-fund based limits from HDFC Bank
- Total bank facilities evaluated stand at Rs 221.30 crore, with Rs 61.55 crore categorized as proposed limits
Q-Line Biotech Limited has filed its quarterly compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018. The report, issued by Purva Sharegistry (India) Pvt. Ltd., confirms that no physical share certificates were received for dematerialization during the period from April 1, 2026, to June 30, 2026. This is a routine administrative filing confirming the maintenance of the company's share register and compliance with depository timelines.
- Zero (NIL) shares were dematerialized during the quarter ended June 30, 2026
- Compliance confirmed for the period starting April 1, 2026, to June 30, 2026
- Registrar and Share Transfer Agent (RTA) confirmed as Purva Sharegistry (India) Pvt. Ltd.
- Filing submitted under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018
நிறுவனச் சுயவிவரம்
நிதிச் செயல்திறன்
இந்த நிறுவனத்துக்கான நிதிப் பகுப்பாய்வுத் தரவு இன்னும் கிடைக்கவில்லை.
செயல்பாட்டு உந்துசக்திகள்
இந்த நிறுவனத்திற்கான செயல்பாட்டுப் பகுப்பாய்வுத் தரவு இன்னும் கிடைக்கவில்லை.
வியூக வளர்ச்சி
இந்த நிறுவனத்துக்கான வியூக வளர்ச்சிப் பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
வெளிப்புறக் காரணிகள்
இந்த நிறுவனத்துக்கு வெளிப்புறக் காரணிகளின் பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
ஒழுங்குமுறை & நிர்வாகம்
இந்த நிறுவனத்திற்கான ஒழுங்குமுறைப் பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
அபாயப் பகுப்பாய்வு
இந்நிறுவனத்துக்கான அபாய பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
